Q2 EPS Estimate for ARS Pharmaceuticals Boosted by Analyst

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Leerink Partnrs boosted their Q2 2025 earnings per share estimates for ARS Pharmaceuticals in a report issued on Sunday, June 22nd. Leerink Partnrs analyst R. Ruiz now forecasts that the company will post earnings of ($0.42) per share for the quarter, up from their prior forecast of ($0.43). The consensus estimate for ARS Pharmaceuticals' current full-year earnings is ($0.55) per share. Leerink Partnrs also issued estimates for ARS Pharmaceuticals' Q4 2025 earnings at ($0.27) EPS, FY2026 earnings at ($0.60) EPS, FY2027 earnings at $0.56 EPS and FY2028 earnings at $2.67 EPS.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.35). The company had revenue of $7.97 million during the quarter, compared to the consensus estimate of $7.48 million. ARS Pharmaceuticals had a negative net margin of 16.11% and a negative return on equity of 6.94%.

Other research analysts also recently issued research reports about the company. Wall Street Zen downgraded ARS Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Scotiabank began coverage on shares of ARS Pharmaceuticals in a research report on Friday, March 7th. They set a "sector outperform" rating and a $30.00 target price for the company. Finally, William Blair reissued an "outperform" rating on shares of ARS Pharmaceuticals in a research note on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $31.00.

ARS Pharmaceuticals Stock Performance

Shares of SPRY stock opened at $16.78 on Wednesday. The stock has a fifty day moving average price of $14.45 and a 200 day moving average price of $12.92. The company has a debt-to-equity ratio of 0.30, a quick ratio of 10.74 and a current ratio of 11.00. The stock has a market cap of $1.65 billion, a PE ratio of -104.87 and a beta of 0.84. ARS Pharmaceuticals has a 1 year low of $7.55 and a 1 year high of $18.51.

Insider Transactions at ARS Pharmaceuticals

In related news, insider Eric Karas sold 15,000 shares of the stock in a transaction dated Wednesday, June 18th. The stock was sold at an average price of $16.00, for a total transaction of $240,000.00. Following the transaction, the insider now directly owns 7,696 shares in the company, valued at approximately $123,136. This represents a 66.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Alexander A. Fitzpatrick sold 102,969 shares of the firm's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $14.10, for a total value of $1,451,862.90. Following the completion of the sale, the insider now directly owns 89,613 shares in the company, valued at approximately $1,263,543.30. The trade was a 53.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 337,971 shares of company stock worth $4,721,888 over the last ninety days. 33.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP grew its holdings in ARS Pharmaceuticals by 0.6% in the fourth quarter. Wellington Management Group LLP now owns 163,252 shares of the company's stock valued at $1,722,000 after purchasing an additional 917 shares during the period. Rhumbline Advisers boosted its holdings in shares of ARS Pharmaceuticals by 2.9% in the 4th quarter. Rhumbline Advisers now owns 65,163 shares of the company's stock valued at $687,000 after purchasing an additional 1,824 shares during the last quarter. Mariner LLC grew its stake in shares of ARS Pharmaceuticals by 5.8% during the 4th quarter. Mariner LLC now owns 35,908 shares of the company's stock valued at $379,000 after buying an additional 1,972 shares during the period. Bank of New York Mellon Corp grew its stake in shares of ARS Pharmaceuticals by 1.5% during the 1st quarter. Bank of New York Mellon Corp now owns 132,213 shares of the company's stock valued at $1,663,000 after buying an additional 1,975 shares during the period. Finally, LPL Financial LLC increased its holdings in shares of ARS Pharmaceuticals by 11.4% during the 4th quarter. LPL Financial LLC now owns 21,408 shares of the company's stock worth $226,000 after buying an additional 2,190 shares during the last quarter. Institutional investors and hedge funds own 68.16% of the company's stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.